Q-omics provides the consensus-scored GRK6 profile across patient tissues and cancer cell-line models. GRK6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GRK6 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, GRK6 protein abundance shows 22,585 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where GRK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRK6 survival associations across molecular data types. GRK6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRK6 RNA expression–survival associations across cancer types. High GRK6 expression shows unfavorable associations in KICH, LIHC, KIRP, LAML, LGG and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GRK6 RNA expression.
This table summarizes GRK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GRK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRK6 shows higher tumor expression in KIRC, KIRP, COAD, LIHC, HNSC and STAD. The KIRC box plot shows higher GRK6 RNA expression in tumor versus normal tissue (log2 FC = +0.889, t-test p < 0.001).
This table shows molecular features associated with GRK6 in patient tissues and cancer cell lines. In patient samples, GRK6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GRK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
